Zydus Lifesciences arm launches generic drugs for cats and dogs in US
Published on 15/09/2025 08:33 PM
Zydus Lifesciences arm launches generic drugs for cats and dogs in USZydus Lifesciences’ subsidiary ZyVet Animal Health has launched FDA-approved generics for urinary incontinence (phenylpropanolamine hydrochloride) and heart failure management (furosemide) in pets. Shares of Zydus Lifesciences Ltd ended lower on Monday (September 15) by 0.84 % at ₹1,036 on the NSE.By Megha Rani September 15, 2025, 8:33:13 PM IST (Published)2 Min ReadZyVet Animal Health, a subsidiary of Zydus Pharmaceuticals (USA) Inc and part of Zydus Lifesciences Ltd, has introduced two FDA-approved generic medicines for animals in the United States.
Phenylpropanolamine hydrochloride tablets for urinary incontinence in dogs and furosemide tablets for managing congestive heart failure and chronic fluid retention in dogs and cats.
Phenylpropanolamine hydrochloride is widely used to treat urinary incontinence linked to urethral sphincter hypotonus, a condition frequently affecting spayed females and older dogs.
The launch provides veterinarians with a lower-cost alternative for long-term management of the disorder, according to the official release.
“Urinary incontinence affects quality of life for both pets and their families. Our phenylpropanolamine hydrochloride tablets deliver on both clinical reliability and affordability,” said Punit Patel, President and CEO, Zydus Americas.
The company also announced the approved generic of furosemide tablets for veterinary use.
Furosemide is one of the most common diuretics prescribed to reduce oedema and pulmonary congestion caused by cardiac, renal, or systemic disease.
Patel noted, “Heart failure and chronic fluid retention require lifelong management, and that often means long-term medication. By offering furosemide as part of our trusted portfolio, we’re helping veterinary teams maintain continuity of care while supporting client adherence.”
Also Read: JSW Infra signs 30-year pact with Kolkata port for berth reconstruction, mechanisation
Shares of Zydus Lifesciences Ltd ended lower on Monday (September 15) by 0.84 % at ₹1,036 on the NSE.Continue Reading(Edited by : Shoma Bhattacharjee)Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!Tagsanimalsus fda approvalZydus Lifesciences